Gastroesophageal Junction Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST012 MIFTS: 47	Gastroesophageal Junction Adenocarcinoma Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma ¹¹ ¹⁴

Adenocarcinoma of the Gastroesophageal Junction ⁷¹

Adenocarcinoma of Cardioesophageal Junction ¹¹

Adenocarcinoma of Gastroesophageal Junction ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4944

NCIt ⁴⁹ C9296

UMLS ⁷¹ C1332166

Sources

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary: Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to esophagus adenocarcinoma and microinvasive gastric cancer, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cetuximab and Gefitinib have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased cell migration

Sources

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 332)

#	Related Disease	Score	Top Affiliating Genes
1	esophagus adenocarcinoma	30.9	TP53 ERBB2 EGFR
2	microinvasive gastric cancer	30.1	VEGFC TP53 ERBB2
3	gastric adenocarcinoma	30.1	TP53 MET FGFR2 ERBB3 ERBB2
4	papillary carcinoma	29.7	VEGFC MET ERBB2
5	exanthem	29.5	VEGFA PDCD1 MTUS2 MTUS1 ERBB2 EGFR
6	adenocarcinoma	29.5	VEGFD VEGFC VEGFA TP53 MET KDR
7	peripheral nervous system disease	29.4	VEGFA TP53 KDR ERBB2 EGFR CTLA4
8	squamous cell carcinoma	29.2	VEGFC VEGFA TP53 MTUS1 FGFR2 ERBB2
9	gastric cancer	28.4	VEGFD VEGFC VEGFA TP53 MET KDR
10	esophageal cancer	27.9	VEGFD VEGFC VEGFA TP53 PDCD1LG2 PDCD1
11	gastroesophageal adenocarcinoma	27.8	VEGFA TP53 PDCD1LG2 PDCD1 MTUS2 MTUS1
12	breast cancer	27.0	VEGFD VEGFC VEGFA TP53 PDCD1 MTUS1
13	neutropenia	10.7
14	factor vii deficiency	10.4
15	barrett esophagus	10.4
16	mucositis	10.4
17	esophagitis	10.4
18	vulva verrucous carcinoma	10.4	PDCD1 CD274
19	gastroesophageal reflux	10.4
20	rhabdomyosarcoma 2	10.4
21	hypoganglionosis	10.3	ERBB3 ERBB2
22	helicobacter pylori infection	10.3
23	stomatitis	10.3
24	angiokeratoma of mibelli	10.3	KDR FLT1
25	conjunctival vascular disease	10.3	VEGFA KDR
26	peptic esophagitis	10.2
27	acneiform dermatitis	10.2	ERBB3 EGFR
28	testicular lymphoma	10.2	PDCD1LG2 PDCD1 CD274
29	type 1 diabetes mellitus 21	10.2	PDCD1LG2 PDCD1 CD274
30	paronychia	10.2	ERBB3 ERBB2 EGFR
31	malignant dermis tumor	10.2	CTLA4 CD274
32	mucinous lung adenocarcinoma	10.2	ERBB3 EGFR
33	vulvar melanoma	10.2	CTLA4 CD274
34	mucosal melanoma	10.2	PDCD1 CTLA4 CD274
35	malignant skin fibrous histiocytoma	10.2	CTLA4 CD274
36	hair disease	10.2	VEGFA ERBB2 EGFR
37	angiokeratoma circumscriptum	10.2	VEGFA KDR FLT1
38	thymus squamous cell carcinoma	10.2	MTUS2 MTUS1
39	capillary hemangioma	10.2	VEGFA KDR FLT1
40	intussusception	10.2	VEGFA KDR FLT1
41	squamous blepharitis	10.2	ERBB3 EGFR
42	capillary disease	10.2	VEGFA KDR FLT1
43	gray zone lymphoma	10.2	PDCD1LG2 CD274
44	rosacea	10.2	VEGFA KDR FLT1
45	thyroid crisis	10.2	MTUS2 MTUS1
46	ovarian hyperstimulation syndrome	10.2	VEGFA KDR FLT1
47	uveal disease	10.2	VEGFA CTLA4 CD274
48	mismatch repair cancer syndrome 1	10.2
49	diarrhea	10.2
50	interstitial lung disease	10.2

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:

Sources

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:

abdominal pain

GenomeRNAi Phenotypes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 41)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-10	10	MET
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-101	10	CD274
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	10	MET
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-119	10	MET
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	10	ERBB3
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10	EGFR
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-127	10	FLT1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10	ERBB2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10	ERBB2
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-171	10	FLT1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10	CLDN18
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-178	10	CLDN18
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-180	10	CD274
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	10	MET
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-187	10	CD274
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-191	10	MET
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-201	10	MET
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	10	ERBB2
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10	EGFR
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10	EGFR
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	10	CD274
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	10	CD274
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-31	10	FLT1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	10	ERBB2
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	10	MET
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-4	10	MET
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10	EGFR
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10	CLDN18
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-53	10	KDR
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-57	10	CLDN18
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	10	ERBB2 ERBB3 KDR
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10	CLDN18 ERBB2 MET
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	10	CLDN18
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-80	10	MET
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10	CD274 EGFR ERBB2 ERBB3 FLT1 KDR
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	10	ERBB2
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-89	10	CLDN18
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10	EGFR
39	Increased cell migration	GR00055-A-1	9.46	KDR VEGFC
40	Increased cell migration	GR00055-A-3	9.46	KDR VEGFC
41	Increased cell viability after pRB stimulation	GR00230-A-1	9.26	EGFR ERBB2 ERBB3 MET

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

⁴⁵ (show all 22)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.48	CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
2	growth/size/body region	MP:0005378	10.38	CLDN18 EGFR ERBB2 ERBB3 FGFR2 FLT1
3	neoplasm	MP:0002006	10.34	EGFR ERBB2 ERBB3 FGFR2 MET MTUS1
4	normal	MP:0002873	10.33	CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
5	nervous system	MP:0003631	10.32	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6	cardiovascular system	MP:0005385	10.31	CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
7	immune system	MP:0005387	10.31	CD274 CLDN18 CTLA4 EGFR ERBB3 FGFR2
8	endocrine/exocrine gland	MP:0005379	10.3	CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
9	muscle	MP:0005369	10.27	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
10	cellular	MP:0005384	10.27	CD274 CLDN18 EGFR ERBB2 ERBB3 FGFR2
11	no phenotypic analysis	MP:0003012	10.19	CD274 EGFR FGFR2 KDR MET PDCD1LG2
12	digestive/alimentary	MP:0005381	10.19	CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
13	liver/biliary system	MP:0005370	10.16	CTLA4 EGFR FGFR2 KDR MET PDCD1
14	embryo	MP:0005380	10.16	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
15	respiratory system	MP:0005388	10.11	CLDN18 CTLA4 EGFR ERBB2 ERBB3 FGFR2
16	craniofacial	MP:0005382	10.02	EGFR ERBB2 FGFR2 KDR MET TP53
17	skeleton	MP:0005390	10.02	CD274 CLDN18 CTLA4 EGFR ERBB2 FGFR2
18	pigmentation	MP:0001186	10	CTLA4 EGFR ERBB3 FGFR2 TP53
19	hematopoietic system	MP:0005397	10	CD274 CLDN18 CTLA4 EGFR ERBB2 FGFR2
20	vision/eye	MP:0005391	9.91	EGFR FGFR2 FLT1 KDR MET PDCD1
21	mortality/aging	MP:0010768	9.89	CD274 CTLA4 EGFR ERBB2 ERBB3 FGFR2
22	integument	MP:0010771	9.28	CD274 CTLA4 EGFR ERBB2 ERBB3 FGFR2

Sources

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cetuximab

Approved

Phase 3

205923-56-4

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Ipilimumab

Approved

Phase 2, Phase 3

477202-00-9

Zanubrutinib

Approved, Investigational

Phase 3

1691249-45-2

135565884

Tucatinib

Approved, Investigational

Phase 2, Phase 3

937263-43-9

51039094

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Docetaxel

Approved, Investigational

Phase 2, Phase 3

114977-28-5

148124

Trastuzumab

Approved, Investigational

Phase 2, Phase 3

180288-69-1

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Epirubicin

Approved

Phase 3

56420-45-2

41867

Adenosine

Approved, Investigational

Phase 2, Phase 3

58-61-7

60961

Rivoceranib

Investigational

Phase 3

811803-05-1

11315474

Bemarituzumab

Investigational

Phase 3

1952272-74-0

Rilotumumab

Investigational

Phase 3

872514-65-3

Protein Kinase Inhibitors

Phase 2, Phase 3

Antimetabolites

Phase 3

Analgesics

Phase 3

Central Nervous System Stimulants

Phase 3

Antiemetics

Phase 3

Opiate Alkaloids

Phase 3

Endothelial Growth Factors

Phase 3

Trastuzumab biosimilar HLX02

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Immunoglobulins, Intravenous

Phase 3

Immunoglobulins

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Pharmaceutical Solutions

Phase 3

Mitogens

Phase 3

Immunoglobulin G

Phase 3

Anti-Bacterial Agents

Phase 3

Antibiotics, Antitubercular

Phase 3

Taxane

Phase 2, Phase 3

108169

Ado-Trastuzumab Emtansine

Phase 2, Phase 3

Maytansine

Phase 2, Phase 3

Raltitrexed

Approved, Investigational

Phase 2

112887-68-0

104758 135400182

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

23431961

Mebendazole

Approved, Vet_approved

Phase 2

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 2

110-85-0

4837

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Durvalumab

Approved, Investigational

Phase 1, Phase 2

1428935-60-7

Interventional clinical trials:

(show top 50) (show all 281)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study	Completed	NCT02426034	Phase 4	ApatinibTablets
2	A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy	Unknown status	NCT04342910	Phase 3	camrelizumab;Apatinib Mesylate;Paclitaxel;Irinotecan
3	A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine	Unknown status	NCT04435652	Phase 2, Phase 3	QL1604;Nab-paclitaxel;Paclitaxel
4	Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction	Unknown status	NCT03986385	Phase 3	Apatinib Capecitabine Oxaliplatin;Capecitabine Oxaliplatin
5	Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma	Unknown status	NCT02193594	Phase 2, Phase 3	Adjuvant chemotherapy
6	Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection	Unknown status	NCT01523015	Phase 2, Phase 3
7	A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction	Unknown status	NCT02409199	Phase 2, Phase 3	Docetaxel;apatinib
8	A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT02625623	Phase 3	Avelumab;Irinotecan;Paclitaxel
9	A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy	Completed	NCT00917384	Phase 3	Placebo
10	A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine	Completed	NCT02370498	Phase 3	paclitaxel
11	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT02545504	Phase 3	Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
12	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)	Completed	NCT02314117	Phase 3	Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
13	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine	Completed	NCT02898077	Phase 3	Ramucirumab;Paclitaxel;Placebo
14	A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients	Completed	NCT01824459	Phase 3	S-1;Oxaliplatin;Cisplatin
15	Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer	Completed	NCT01962246	Phase 2, Phase 3	Oxaliplatin; Capecitabine
16	Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen	Completed	NCT01640782	Phase 3	Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
17	Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma	Completed	NCT00978549	Phase 3	docetaxel;steroid therapy
18	Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial	Completed	NCT01107639	Phase 3	cisplatin;docetaxel
19	Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy	Completed	NCT01243398	Phase 3
20	Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction	Completed	NCT00678535	Phase 3	Cetuximab;Capecitabine;Cisplatin
21	Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer	Recruiting	NCT03801876	Phase 3	Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
22	A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma	Recruiting	NCT03604991	Phase 2, Phase 3	Carboplatin;Paclitaxel
23	An International, Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma After Radical Gastrectomy	Recruiting	NCT05180734	Phase 3
24	A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)	Recruiting	NCT05002127	Phase 2, Phase 3	Evorpacept (ALX148);Trastuzumab;Ramucirumab;Paclitaxel
25	A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)	Recruiting	NCT04704934	Phase 3	Trastuzumab deruxtecan;Ramucirumab;Paclitaxel
26	RACE-trial: Neoadjuvant Radiochemotherapy Versus Chemotherapy for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A Randomized Phase III Joint Study of the AIO, ARO and DGAV	Recruiting	NCT04375605	Phase 3	5-Fluorouracil;Calcium folinate;Oxaliplatin;Docetaxel;Oxaliplatin during radiotherapy;5-Fluorouracil during radiotherapy
27	A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Recruiting	NCT05052801	Phase 3	Bemarituzumab;mFOLFOX6;Placebo
28	Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO	Recruiting	NCT04447352	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Cisplatin
29	A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression	Recruiting	NCT05111626	Phase 3	Bemarituzumab;Nivolumab;mFOLFOX6
30	A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma	Recruiting	NCT05008783	Phase 3	AK104;Placebo
31	A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib	Active, not recruiting	NCT00680901	Phase 3	Lapatinib;Placebo;Capecitabine;Oxaliplatin
32	A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)	Active, not recruiting	NCT04675983	Phase 3	Sintilimab;Ramucirumab;Cisplatin;5-fluorouracil;Oxaliplatin;Capecitabine
33	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Active, not recruiting	NCT03777657	Phase 3	Tislelizumab;Placebo;Cisplatin;Oxaliplatin;Capecitabine;5-FU
34	A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)	Active, not recruiting	NCT03615326	Phase 3	Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
35	A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)	Active, not recruiting	NCT04499924	Phase 2, Phase 3	tucatinib;trastuzumab;ramucirumab;paclitaxel
36	A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With CAPOX Chemotherapy Compared to Placebo in Combination With CAPOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma	Active, not recruiting	NCT03802591	Phase 3	CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
37	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
38	A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine	Terminated	NCT03019588	Phase 3	Paclitaxel
39	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma	Terminated	NCT02137343	Phase 3	Rilotumumab;Placebo;Cisplatin;Capecitabine
40	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma	Terminated	NCT01697072	Phase 3	Rilotumumab;Epirubicin;Cisplatin;Capecitabine
41	A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction	Terminated	NCT01641939	Phase 2, Phase 3	Taxane;trastuzumab emtansine
42	A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine	Unknown status	NCT04555304	Phase 2	KH903 + Paclitaxel;Placebo + Paclitaxel
43	Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis	Unknown status	NCT02589496	Phase 2	pembrolizumab
44	Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT00763646	Phase 2	Taxotere, Cisplatin, and 5-FU
45	Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT02525237	Phase 2	Apatinib;S-1
46	A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT03219593	Phase 2	Apatinib mesylate tablets
47	Safety and Efficacy Evaluation of Capecitabine, Cisplatin, and Herzuma Combination Chemotherapy for the First Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients.	Unknown status	NCT03588533	Phase 2	Trastuzumab;Capecitabine;Cisplatin
48	Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT03950271	Phase 2	SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
49	A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT01379807	Phase 2	panitumumab + docetaxel + cisplatino
50	A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction	Unknown status	NCT03349866	Phase 2	apatinib;Capecitabine;Oxaliplatin

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Sources

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Sources

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

Organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

MalaCards : Breast, Pancreas, T Cells, Lung, Liver, Endothelial, Lymph Node

Sources

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 347)

#	Title	Authors	PMID	Year
1	Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective. ⁶²	Qu T...Enzinger PC	36241842	2022
2	Esophageal Grape-Like Lesion in a 41-Year-Old Man With a History of Gastroesophageal Junction Adenocarcinoma. ⁶²	Le PH...Wu RC	35728687	2022
3	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. ⁶²	Kim JM...Kim KM	36125657	2022
4	Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort. ⁶²	Manfredi S...Metestomac Investigators/Collaborators	36394147	2022
5	Recurrent Disease After Esophageal Cancer Surgery: A Substudy of The Dutch Nationwide Ivory Study. ⁶²	Kalff MC...Gisbertz SS	35880759	2022
6	[Clinical characteristics of digestive system cancers metastatic to the heart]. ⁶²	Tang JL...Huang J	36380673	2022
7	Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. ⁶²	Zhang Y...Xu RH	36384091	2022
8	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. ⁶²	Jing C...Deng W	35304622	2022
9	The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis. ⁶²	Wang T...Shen L	36352476	2022
10	Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. ⁶²	Yamaguchi K...Shitara K	36379002	2022
11	Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment? ⁶²	Perez Holguin RA...Peng JS	36042124	2022
12	Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma. ⁶²	Brotherton T...Presti M	36212240	2022
13	Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma? ⁶²	Mori M...Fiorino C	36114920	2022
14	The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. ⁶²	Lu Z...Shen L	35778636	2022
15	Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. ⁶²	Grizzi G...Celotti A	35704113	2022
16	Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST. ⁶²	Salati M...Gelmini R	36143086	2022
17	HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives. ⁶²	Li W...Zhao J	36175985	2022
18	Tandem mass tagging combined with liquid chromatography-tandem mass spectrometry technique to detect protein markers in gastroesophageal junction adenocarcinoma. ⁶²	Zheng X...Li S	35840340	2022
19	Preoperative radiotherapy affects the prognosis of patients with stage T1-3N0-1M0 gastroesophageal junction adenocarcinoma. ⁶²	Yang W...Han B	35961911	2022
20	Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection. ⁶²	Kang WZ...Tian YT	36160743	2022
21	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. ⁶²	Lee KW...Wyrwicz L	35657979	2022
22	T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. ⁶²	Shah MA...Kato K	35852104	2022
23	Correction to: Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC). ⁶²	Bouriez D...Collet D	35523994	2022
24	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. ⁶²	Businello G...Fassan M	35834132	2022
25	Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. ⁶²	Shi J...Jin J	35902798	2022
26	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ⁶²	Shah MA...Van Cutsem E	35833783	2022
27	Treatment heterogeneity and overall survival in patients with advanced/metastatic gastric or gastroesophageal junction adenocarcinoma in the United States. ⁶²	Davis JA...Hess LM	35837150	2022
28	Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. ⁶²	Nishikawa G...Chen EY	35837173	2022
29	Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC). ⁶²	Bouriez D...Collet D	35430699	2022
30	Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma. ⁶²	Rogers JE...Ajani JA	35695051	2022
31	Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study. ⁶²	Zhang Y...Shen B	35813347	2022
32	Proportion of Early-Onset Gastric and Esophagus Cancers Has Changed Over Time With Disproportionate Impact on Black and Hispanic Patients. ⁶²	Torrejon NV...Kamath SD	35544654	2022
33	The impact of hiatal hernia on survival outcomes in patients with gastroesophageal junction adenocarcinoma. ⁶²	Tanaka Y...Tomi Y	35634180	2022
34	Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma. ⁶²	Shah MA...Van Cutsem E	35617520	2022
35	Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. ⁶²	Basoglu T...Yumuk PF	35579894	2022
36	Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. ⁶²	Wood AC...Mehta R	35380714	2022
37	Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. ⁶²	Jiang H...Teng L	35296556	2022
38	Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. ⁶²	Gourzoulidis G...Kourlaba G	33900864	2022
39	Esophageal Adenocarcinoma in an Active Duty Sailor: A Case Report. ⁶²	Wilson BF...Cowler T	35355077	2022
40	Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma. ⁶²	Jin X...Bai Y	34677650	2022
41	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. ⁶²	Shah MA...Ajani JA	35267477	2022
42	Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study. ⁶²	Yan Y...He Y	35280426	2022
43	A case of severe vasculitis after FLOT chemotherapy in a patient with metastatic gastric cancer who received multiple line chemotherapy. ⁶²	Hendem E...Artac M	35044279	2022
44	Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries. ⁶²	Manabe N...Haruma K	34718236	2022
45	Metastatic esophageal cancer presenting as bladder mass, a case report. ⁶²	Liu S...Cahn DB	34849343	2022
46	Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study. ⁶²	Li LH...Wu G	35531474	2022
47	Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. ⁶²	Yoshikawa AK...Satoh T	34992093	2022
48	Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma. ⁶²	Wang Y...Yao Y	36330490	2022
49	New Horizons for Personalised Treatment in Gastroesophageal Cancer. ⁶²	Salati M...Spallanzani A	35054006	2022
50	Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II-III gastroesophageal junction adenocarcinoma: A large population-based cohort study. ⁶²	Zuo Z...Liu Y	36338703	2022

Sources

Genes for Gastroesophageal Junction Adenocarcinoma

Genes related to Gastroesophageal Junction Adenocarcinoma (0 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.12	DISEASES inferred ¹⁴
2	KDR	Kinase Insert Domain Receptor	Protein Coding	6.77	DISEASES inferred ¹⁴
3	CD274	CD274 Molecule	Protein Coding	6.65	DISEASES inferred ¹⁴
4	CLDN18	Claudin 18	Protein Coding	6.3	DISEASES inferred ¹⁴
5	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.98	DISEASES inferred ¹⁴
6	PDCD1	Programmed Cell Death 1	Protein Coding	5.89	DISEASES inferred ¹⁴
7	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.75	DISEASES inferred ¹⁴
8	PDCD1LG2	Programmed Cell Death 1 Ligand 2	Protein Coding	5.5	DISEASES inferred ¹⁴
9	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	5.42	DISEASES inferred ¹⁴
10	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	5.31	DISEASES inferred ¹⁴
11	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	5.31	DISEASES inferred ¹⁴
12	MTUS1	Microtubule Associated Scaffold Protein 1	Protein Coding	5.3	DISEASES inferred ¹⁴
13	MTUS2	Microtubule Associated Scaffold Protein 2	Protein Coding	5.28	DISEASES inferred ¹⁴
14	VEGFC	Vascular Endothelial Growth Factor C	Protein Coding	5.17	DISEASES inferred ¹⁴
15	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	5.08	DISEASES inferred ¹⁴
16	VEGFD	Vascular Endothelial Growth Factor D	Protein Coding	5.07	DISEASES inferred ¹⁴
17	TP53	Tumor Protein P53	Protein Coding	5.03	DISEASES inferred ¹⁴
18	VEGFB	Vascular Endothelial Growth Factor B	Protein Coding	5	DISEASES inferred ¹⁴
19	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	4.98	DISEASES inferred ¹⁴

Sources

Variations for Gastroesophageal Junction Adenocarcinoma

Sources

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Sources

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 78)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.9	VEGFD VEGFC VEGFB VEGFA TP53 MET
2	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.87	VEGFD VEGFC VEGFB TP53 MET KDR
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.83	VEGFA TP53 PDCD1 MET KDR FGFR2
4	Signal Transduction ⁶⁶	13.83	VEGFD VEGFC VEGFB VEGFA TP53 MET
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.76	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.68	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
7	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.64	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
8	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.58	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
9	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.52	VEGFA TP53 MET KDR FGFR2 ERBB3
10	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.47	VEGFD VEGFC VEGFB TP53 MET KDR
11	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.42	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
12	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.39	EGFR ERBB2 FGFR2 FLT1 KDR MET
13	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.34	VEGFD VEGFC VEGFB VEGFA MET KDR
14	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.17	VEGFD VEGFC VEGFB TP53 MET KDR
15	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.15	VEGFD VEGFC VEGFB MET KDR FLT1
16	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.11	TP53 MET FGFR2 ERBB3 ERBB2 EGFR
17	Actin Nucleation by ARP-WASP Complex ⁶⁴ Show member pathways Actin Nucleation and Branching ⁶⁴ CDC42 Pathway ⁶⁴ RhoA Pathway ⁶⁴	13.06	MET KDR FLT1 FGFR2 ERBB3 ERBB2
18	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13	VEGFD VEGFC VEGFB VEGFA TP53 MET
19	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.8	VEGFA TP53 KDR FGFR2 ERBB2 EGFR
20	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.8	VEGFD VEGFC VEGFB MET KDR FLT1
21	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.73	MET FGFR2 ERBB3 ERBB2 EGFR
22	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.72	VEGFD VEGFC VEGFB TP53 MET KDR
23	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.56	VEGFD VEGFC VEGFB VEGFA KDR FLT1
24	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.53	TP53 ERBB3 ERBB2 EGFR
25	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.53	TP53 MET KDR FLT1 FGFR2 ERBB3
26	Malignant pleural mesothelioma ⁷⁴	12.51	CD274 EGFR FGFR2 FLT1 KDR MET
27	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.48	TP53 MET ERBB3 ERBB2
28	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.48	TP53 FGFR2 ERBB2 EGFR
29	Signaling by VEGF ⁶⁶ Show member pathways VEGFA-VEGFR2 Pathway ⁶⁶	12.45	FLT1 KDR VEGFA VEGFB VEGFC VEGFD
30	RhoGDI Pathway ⁶⁴ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶⁴	12.44	EGFR FGFR2 FLT1 KDR MET VEGFA
31	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.43	CD274 CTLA4 PDCD1 PDCD1LG2
32	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.42	VEGFD VEGFC VEGFB MET KDR FLT1
33	Ras signaling ⁷⁴	12.36	MET KDR FLT1 FGFR2 EGFR
34	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.32	EGFR FGFR2 FLT1 KDR VEGFA VEGFB
35	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.31	TP53 MET KDR FLT1 FGFR2 ERBB3
36	Focal adhesion ⁷⁴	12.27	VEGFD VEGFC VEGFB VEGFA MET KDR
37	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.12	VEGFD VEGFC VEGFB VEGFA MET KDR
38	mTOR Signaling ⁶⁵	12.11	TP53 MET KDR FLT1 FGFR2 ERBB3
39	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.1	TP53 ERBB3 ERBB2 EGFR
40	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	12.02	MET KDR FLT1 FGFR2 EGFR
41	Angiogenesis (CST) ³	12	VEGFC VEGFB KDR FLT1 FGFR2
42	Clear cell renal cell carcinoma pathways ⁷⁴	11.93	EGFR FLT1 KDR VEGFA
43	Head and neck squamous cell carcinoma ⁷⁴	11.9	VEGFA TP53 FGFR2 ERBB2 EGFR
44	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.88	VEGFA ERBB2 EGFR
45	G-protein signaling_RhoA regulation pathway ²²	11.86	VEGFD VEGFC VEGFB FGFR2 ERBB3 ERBB2
46	Phosphorylation of CD3 and TCR zeta chains ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶	11.82	PDCD1LG2 PDCD1 CD274
47	Burn wound healing ⁷⁴	11.79	VEGFA TP53 FGFR2
48	Tyrosine Kinases / Adaptors ³	11.78	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
49	Transcription_P53 signaling pathway ²²	11.76	VEGFA TP53 KDR FLT1
50	SHP2 signaling ⁶¹	11.73	VEGFA KDR FGFR2 EGFR

Sources

GO Terms for Gastroesophageal Junction Adenocarcinoma

Cellular components related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.97	CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
2	membrane	GO:0016020	10.97	CD274 CLDN18 CTLA4 EGFR ERBB2 ERBB3
3	plasma membrane	GO:0005887	10.45	CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
4	plasma membrane	GO:0005886	10.45	CTLA4 EGFR ERBB2 ERBB3 FGFR2 FLT1
5	extracellular region	GO:0005576	10.43	VEGFD VEGFC VEGFB VEGFA PDCD1LG2 MET
6	platelet alpha granule lumen	GO:0031093	9.92	VEGFD VEGFC VEGFB VEGFA
7	basal plasma membrane	GO:0009925	9.86	EGFR ERBB2 ERBB3 MET
8	ERBB3:ERBB2 complex	GO:0038143	9.71	ERBB3 ERBB2
9	receptor complex	GO:0043235	9.47	MET KDR FLT1 FGFR2 ERBB3 ERBB2
10	plasma membrane region	GO:0098590	9.33	ERBB3 ERBB2 EGFR
11	obsolete spanning component of plasma membrane	GO:0044214	9.13	ERBB3 ERBB2 EGFR

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 41)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface receptor signaling pathway	GO:0007166	10.37	CD274 EGFR ERBB2 MET PDCD1LG2
2	positive regulation of protein phosphorylation	GO:0001934	10.37	VEGFD VEGFC VEGFB VEGFA KDR ERBB2
3	positive regulation of cell population proliferation	GO:0008284	10.35	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
4	negative regulation of apoptotic process	GO:0043066	10.34	VEGFB VEGFA TP53 KDR ERBB3 ERBB2
5	positive regulation of cell migration	GO:0030335	10.31	VEGFC VEGFA KDR FLT1 EGFR CD274
6	positive regulation of angiogenesis	GO:0045766	10.31	FLT1 KDR VEGFA VEGFB VEGFC VEGFD
7	protein autophosphorylation	GO:0046777	10.3	EGFR ERBB2 FGFR2 FLT1 KDR
8	response to hypoxia	GO:0001666	10.28	VEGFD VEGFC VEGFB VEGFA
9	protein phosphorylation	GO:0006468	10.28	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
10	angiogenesis	GO:0001525	10.28	VEGFD VEGFC VEGFA KDR FLT1 FGFR2
11	peptidyl-tyrosine phosphorylation	GO:0018108	10.27	MET KDR FLT1 FGFR2 ERBB3 ERBB2
12	positive regulation of endothelial cell proliferation	GO:0001938	10.25	VEGFD VEGFC VEGFB VEGFA KDR
13	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.25	MET KDR FLT1 FGFR2 ERBB3 ERBB2
14	positive regulation of MAPK cascade	GO:0043410	10.24	ERBB2 FGFR2 FLT1 KDR VEGFA
15	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.23	VEGFB VEGFA KDR FGFR2 EGFR
16	positive regulation of MAP kinase activity	GO:0043406	10.21	VEGFA FLT1 ERBB2 EGFR
17	positive regulation of cell division	GO:0051781	10.21	FGFR2 VEGFA VEGFB VEGFC VEGFD
18	positive chemotaxis	GO:0050918	10.18	MET VEGFA VEGFB VEGFC VEGFD
19	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.16	VEGFA KDR FLT1 ERBB3
20	sprouting angiogenesis	GO:0002040	10.16	VEGFA VEGFB VEGFC VEGFD
21	negative regulation of T cell proliferation	GO:0042130	10.15	PDCD1LG2 CTLA4 CD274
22	positive regulation of blood vessel endothelial cell migration	GO:0043536	10.14	VEGFC VEGFA KDR
23	positive regulation of protein kinase B signaling	GO:0051897	10.13	VEGFB VEGFA MET EGFR
24	positive regulation of epithelial cell proliferation	GO:0050679	10.13	EGFR ERBB2 FGFR2 KDR VEGFA VEGFC
25	cellular response to vascular endothelial growth factor stimulus	GO:0035924	10.12	VEGFA KDR FLT1
26	phosphorylation	GO:0016310	10.12	MET KDR FLT1 FGFR2 ERBB3 ERBB2
27	regulation of ERK1 and ERK2 cascade	GO:0070372	10.1	FGFR2 ERBB2 EGFR
28	induction of positive chemotaxis	GO:0050930	10.1	VEGFD VEGFC VEGFB VEGFA
29	positive regulation of kinase activity	GO:0033674	10.1	MET KDR FLT1 FGFR2 ERBB3 ERBB2
30	vascular wound healing	GO:0061042	9.99	VEGFA KDR
31	ERBB2-EGFR signaling pathway	GO:0038134	9.98	ERBB2 EGFR
32	vascular endothelial growth factor receptor-2 signaling pathway	GO:0036324	9.96	KDR VEGFA
33	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	9.96	KDR VEGFA
34	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.96	TP53 VEGFA
35	ERBB2-ERBB3 signaling pathway	GO:0038133	9.95	ERBB3 ERBB2
36	positive regulation of phosphorylation	GO:0042327	9.94	EGFR KDR VEGFA
37	positive regulation of mast cell chemotaxis	GO:0060754	9.92	VEGFA VEGFB VEGFC VEGFD
38	vascular endothelial growth factor receptor signaling pathway	GO:0048010	9.73	VEGFD VEGFC VEGFB VEGFA KDR FLT1
39	multicellular organism development	GO:0007275	9.7	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
40	positive regulation of miRNA maturation	GO:1903800	9.67	TP53 EGFR
41	vascular endothelial growth factor signaling pathway	GO:0038084	9.4	VEGFD VEGFC VEGFB VEGFA KDR FLT1

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.51	VEGFD VEGFB VEGFA TP53 MET KDR
2	protein phosphatase binding	GO:0019903	10.08	TP53 MET ERBB2 EGFR
3	kinase activity	GO:0016301	9.95	MET KDR FLT1 FGFR2 ERBB3 ERBB2
4	growth factor binding	GO:0019838	9.92	KDR FLT1 ERBB3 ERBB2
5	protein kinase activity	GO:0004672	9.91	EGFR ERBB2 ERBB3 FGFR2 FLT1 KDR
6	chemoattractant activity	GO:0042056	9.86	VEGFD VEGFC VEGFB VEGFA
7	vascular endothelial growth factor receptor activity	GO:0005021	9.84	KDR FLT1
8	ErbB-3 class receptor binding	GO:0043125	9.83	ERBB3 ERBB2
9	receptor ligand activity	GO:0048018	9.83	VEGFD VEGFC VEGFB VEGFA
10	vascular endothelial growth factor receptor 1 binding	GO:0043183	9.8	VEGFA VEGFB
11	protein tyrosine kinase activity	GO:0004713	9.77	MET KDR FLT1 FGFR2 ERBB3 ERBB2
12	vascular endothelial growth factor receptor 3 binding	GO:0043185	9.76	VEGFD VEGFC
13	vascular endothelial growth factor receptor binding	GO:0005172	9.76	VEGFA VEGFB VEGFC VEGFD
14	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.44	MET KDR FLT1 FGFR2 ERBB3 ERBB2